US009408821B2

(12) **United States Patent**
Maeda et al.

(10) **Patent No.: US 9,408,821 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION**

(75) Inventors: **Tadao Maeda**, Mayfield Heights, OH (US); **David Saperstein**, Seattle, WA (US); **Krzysztof Palczewski**, Bay Village, OH (US)

(73) Assignee: **University of Washington**, Seattle, WA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/619,947**

(22) Filed: **Sep. 14, 2012**

(65) **Prior Publication Data**

US 2013/0072557 A1 Mar. 21, 2013

Related U.S. Application Data

(63) Continuation of application No. 12/368,427, filed on Feb. 10, 2009, now Pat. No. 8,324,270.

(60) Provisional application No. 61/027,625, filed on Feb. 11, 2008.

(51) **Int. Cl.**

A61K 31/215	(2006.01)
A61K 31/4709	(2006.01)
A61K 31/07	(2006.01)
A61K 31/22	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/215*** (2013.01); ***A61K 31/07*** (2013.01); ***A61K 31/22*** (2013.01); ***A61K 31/4709*** (2013.01); *Y10S 514/912* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,196,078	A	7/1965	Chatzinoff et al.	
3,517,067	A	6/1970	Stern	
5,457,135	A	10/1995	Baranowitz et al.	
5,620,970	A	4/1997	Han et al.	
5,837,728	A	11/1998	Purcell	
5,869,468	A	2/1999	Freeman	
6,300,328	B1	10/2001	Klimko	
6,552,009	B2	4/2003	Achkar	
6,696,069	B2	2/2004	Harichian et al.	
7,566,808	B2	7/2009	Rando	
7,951,841	B2 *	5/2011	Palczewski et al.	514/529
8,324,270	B2 *	12/2012	Maeda et al.	514/529
8,962,691	B2	2/2015	Palczewski et al.	
9,149,446	B2	10/2015	Palczewski et al.	
9,162,978	B2	10/2015	Palczewski et al.	
9,169,204	B2	10/2015	Palczewski et al.	
9,174,936	B2 *	11/2015	Palczewski	C07C 403/10
9,233,091	B2	1/2016	Maeda et al.	
2002/0028849	A1	3/2002	Godkin et al.	
2003/0215413	A1	11/2003	Fares et al.	
2003/0228277	A1	12/2003	Gehlsen	
2004/0022766	A1	2/2004	Acland et al.	
2004/0097587	A1	5/2004	Arbiser	
2004/0242704	A1	12/2004	Palczewski et al.	
2006/0167088	A1	7/2006	Widder et al.	
2006/0281821	A1	12/2006	Palczewski	
2008/0221208	A1	9/2008	Palczewski et al.	
2008/0275133	A1	11/2008	Schwartz et al.	
2010/0035986	A1	2/2010	Maeda et al.	
2011/0034554	A1	2/2011	Washington	
2011/0288170	A1	11/2011	Palczewski et al.	
2012/0041073	A1	2/2012	Palczewski et al.	
2012/0322891	A1	12/2012	Palczewski et al.	
2013/0072443	A1	3/2013	Palczewski et al.	
2013/0072556	A1	3/2013	Palczewski et al.	
2013/0072557	A1	3/2013	Maeda et al.	
2013/0072558	A1	3/2013	Maeda et al.	
2013/0072559	A1	3/2013	Palczewski et al.	
2013/0072560	A1	3/2013	Palczewski et al.	
2013/0072561	A1	3/2013	Maeda et al.	
2013/0072568	A1	3/2013	Palczewski et al.	
2013/0072569	A1	3/2013	Palczewski et al.	
2013/0079403	A1	3/2013	Palczewski et al.	
2013/0196950	A1	8/2013	Palczewski et al.	

FOREIGN PATENT DOCUMENTS

CA	2601278	A1	9/2005
CN	1169854	A	1/1998
CN	1455780	A	11/2003

(Continued)

OTHER PUBLICATIONS

Owsley et al., Delays in rod-mediated dark adaptation in early age-related maculopathy, Ophthalmology. Jul. 2001;108(7):1196-202, http://www.ncbi.nlm.nih.gov/pubmed/11425675, 1 page, Abstract only.*

Gaffney et al., Aging and cone dark adaptation, Optom Vis Sci. Aug. 2012;89(8):1219-24, printed from http://www.ncbi.nlm.nih.gov/pubmed/22773176, Abstract only, 1 page.*

Chan et al., Delayed Dark Adaptation Caused by Nilutamide, Journal of Neuro-Ophthalmology: Jun. 2008—vol. 28—Issue 2—pp. 158-159.*

Marmor et al., Albipunctate retinopathy with cone dysfunction and no abnormality in the RDH5 or RLBP1 genes, Retina. Aug. 2003;23(4):543-6.*

Jackson et al, Aging and dark adaptation, Vision Res. Nov. 1999;39(23):3975-82, printed from http://www.ncbi.nlm.nih.gov/pubmed/10748929, 1 page, abstract only.*

Ablonczy et al., "11-cis-retinyl reduces constitutive phosphorylyzation and improves quantum catch in retinoid-deficient mouse rod photoreceptors", J. Biol. Chem., vol. 277, pp. 40491-40498 (2002).

Acland et al., "Gene therapy restores vision in a canine model of childhood blindness", Nature Genetics, vol. 28, pp. 92-95 (2001).

(Continued)

Primary Examiner — Gigi Huang

(74) *Attorney, Agent, or Firm* — Jacqueline F. Mahoney; Judy M. Mohr; McDermott Will & Emery LLP

(57) **ABSTRACT**

A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C_1-C_{10} monocarboxylic acids and C_2-C_{22} polycarboxylic acids.

14 Claims, 9 Drawing Sheets